Literature DB >> 17891057

Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy.

K Ishikawa1, S Honda, Y Tsukahara, A Negi.   

Abstract

PURPOSE: To evaluate the safety and efficacy of intravitreal injection of bevacizumab advanced to vitrectomy for severe proliferative diabetic retinopathy.
METHODS: Eight eyes of six patients (33-64 years old, all male patients) with severe proliferative diabetic retinopathy were investigated. An intravitreal injection of 1.25 mg bevacizumab was performed 3-30 days prior to planned vitrectomy.
RESULTS: All cases showed minimum bleeding during surgical dissection of fibrovascular membrane. Two cases receiving bevacizumab 7 days before the surgery showed strong fibrosis and adhesion of fibrovascular membrane, resulted in some surgical complications. The cases having intravitreal bevacizumab for shorter time did not show extensive fibrosis.
CONCLUSIONS: The pretreatment of bevacizumab is likely effective in the vitrectomy for severe PDR. The appropriate timing of vitrectomy after bevacizumab injection should be further evaluated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17891057     DOI: 10.1038/sj.eye.6702983

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  29 in total

1.  Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.

Authors:  Shigeru Honda; Hiroaki Hirabayashi; Yasutomo Tsukahara; Akira Negi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-03-05       Impact factor: 3.117

2.  Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study.

Authors:  Dong Ho Park; Jae Pil Shin; Si Yeol Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-12       Impact factor: 3.117

3.  Bevacizumab prior to vitrectomy for diabetic traction retinal detachment.

Authors:  R Pokroy; U R Desai; E Du; Y Li; P Edwards
Journal:  Eye (Lond)       Date:  2011-07-08       Impact factor: 3.775

Review 4.  A review of anti-VEGF agents for proliferative diabetic retinopathy.

Authors:  P Osaadon; X J Fagan; T Lifshitz; J Levy
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

5.  Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Authors:  Farzin Forooghian; Peter J Kertes; Kenneth T Eng; Elvira Agrón; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

6.  Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity: a case report.

Authors:  Hae Jung Sun; Kyung Seek Choi; Sung Jin Lee
Journal:  Jpn J Ophthalmol       Date:  2012-07-28       Impact factor: 2.447

7.  Current concepts in intravitreal drug therapy for diabetic retinopathy.

Authors:  Anant Pai; Maha M El Shafei; Osman A Z Mohammed; Mustafa Al Hashimi
Journal:  Saudi J Ophthalmol       Date:  2010-06-30

Review 8.  Surgery for Diabetic Eye Complications.

Authors:  María H Berrocal; Luis A Acaba; Alexandra Acaba
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

Review 9.  Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy.

Authors:  R Simó; C Hernández
Journal:  Diabetologia       Date:  2008-04-11       Impact factor: 10.122

10.  Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series.

Authors:  Carlos Gustavo Vasconcelos de Moraes; Antonio Carlos Facio; José Humberto Costa; Roberto Freire Santiago Malta
Journal:  J Ocul Biol Dis Infor       Date:  2009-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.